AVE-0010. GLP-1 receptor agonist, treatment of diabetes

Drugs of the Future

Volumn 33, Issue 10, 2008, Pages 838-840

  Campas C ^a   Castaner R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AVE 0010; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; HIS GLY GLN GLY THR PHE THR SER ASP LEU SER LYS GLN MET GLN GLN GLN ALA VAL ARG LEU PHE ILE GLN TRP LEU LYS ASP GLY GLY PROPYLSERYL SER GLY ALA PROPYL PROPYLSERYL LYS LYS LYS LYS LYS LYSYLAMIDE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ZP 10; ZP 10A;

ARTICLE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RISK BENEFIT ANALYSIS; SLOW RELEASE FORMULATION; VOMITING;

EID: 58349087226     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.33.10.1265206     Document Type: Article

References (19)

1. Smyth, S., Heron, A. Diabetes and obesity: The twin epidemics. Nat Mad 2006, 12(1): 75.
2. Hoist J.J. The physiology of glucagon-like peptide 1. Physioll Rev 2007, 87(4): 1409-39.
3. Van Gaal, L.F., Gutkin, S.W., Nauck, M.A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008, 158(6): 773-84.
4. Thorkildsen, C., Neve, S., Larsen, B.D., Meier, E., Petersen, J.S. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003, 307(2): 490-6.
5. Tews, D., Werner, U., Eckel, J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008, 40(3): 172-80.
6. Haschke, G., Haag-Diegarten, S., Werner, U., Kramer, W., Herling, A.W. The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - An isolated perfused pancreas study. 42nd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 14-17, Copenhagen) 2006, Abst 0659.
7. Werner, U., Gerlach, M., Hofmann, M., Herling, A.W. Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist A VE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia. 42nd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 14-17, Copenhagen) 2006, Abst 0656.
8. Werner, U., Gerlach, M., Hofmann, M., Herling, A.W. The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycemia. 67th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 486-P.
9. Moore, M.C., Werner, U., Smith, M.S., Rodewald, T.D., Cherrington, A.D. Effect of the glucagon-like peptide-1 receptor agonistAVE0010 on postprandial hepatic glucose metabolism in the conscious dog. 43rd Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 17-21, Amsterdam) 2007, Abst 0584.
10. Distiller, L., Ruus, P.E. Pharmacokinetics and pharmacodynamics of GLP-1 agonist A VE0010 in type 2 diabetes patients. Diabetes 2008, 57(Suppl. 1): Abst 520-P.
11. Ratner, R. E., Rosenstock, J., Boka, G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin. Diabetes 2008, 57(Suppl. 1): Abst 433-P.
12. Rosenstock, J., Ratner, R.E., Boka, G. Dose range effects of the new once daily GLP-1 receptor agonist A VE0010 added to metformin in type 2 diabetes. Diabetologia 2008, 51(Suppl. 1): Abst 145.
13. GLP- 1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation in monotherapy (GETGOAL-MONO) (NCT00688701). ClinicalTrials,gov Web site, October 20, 2008.
14. GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-F1) (NCT00763451). ClinicalTrials.gov Web site, October 20, 2008.
15. GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL-S) (NCT00713830). ClinicalTrials.gov Web site, October 20, 2008.
16. GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of basal insulin (GETGOAL-L) (NCT00715624). CliniGalTrials.gov Web site, October 20, 2008.
17. GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL-P) (NCT00763815). ClinicalTrials.gov Web site, October 20, 2008.
18. GLP-1 agonist AVE0010 (morning or evening) in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-M) (NCT00712673). ClinicalTrials.gov Web site, October 20, 2008.
19. GLP-1 agonist AVE0010 versus exenatide in patients with type2diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-X) (NCT00707031). ClinicalTrials.gov Web site, October 20, 2008.